Adocia Is A Clinical Stage Biotechnology Company Based In Francefounded In 2005The Company Is Dedicated To Developing Innovative Medicines For Metabolic Diseasesparticularly Diabetes And Obesityadocia Specializes In Advanced Formulations Of Approved Peptides And Proteinsutilizing Proprietary Technologies To Enhance Therapeutic Outcomes The Companyae S Product Portfolio Includes The Biochaperoneatechnology Platformwhich Improves The Stability And Absorption Of Therapeutic Peptidesnotable Products Include Biochaperonealisproan Ultra Rapid Insulin Formulation In Phase 3 Clinical Trialsand Biochaperoneacomboa Fixed Combination Of Long Acting And Rapid Acting Insulins Available For Partneringadocia Is Also Developing Immunoprotective Scaffolds For Cell Therapies Aimed At Diabetes And Obesity Adocia Focuses On Research And Developmentadvancing Its Products Through Clinical Stages Before Licensing Them To Partners For Commercializationthe Company Targets Patients With Metabolic Diseases And Collaborates With Pharmaceutical And Biotech Firms To Expand The Reach Of Its Innovative Treatments Globally
